Literature DB >> 6235335

Coagulopathy and platelet activation in Kawasaki syndrome: identification of patients at high risk for development of coronary artery aneurysms.

J C Burns, M P Glode, S H Clarke, J Wiggins, W E Hathaway.   

Abstract

Prospective evaluation of platelet activation and hypercoagulability was performed in 31 patients with Kawasaki syndrome. Most patients had elevated acute-phase reactants when studied during the first 3 weeks of their illness; 17 of 25 (68%) patients had factor VIII activity greater than 150%, 18 of 24 (75%) had fibrinogen greater than 400 mg/dl, and 17 of 31 (55%) had a platelet count greater than 450,000/mm3. Antithrombin III was depressed initially in 17 of 25 (68%) patients. Depleted fibrinolytic activity, as measured by a euglobulin lysis time greater than 300 minutes, was documented in nine of 20 (45%) patients. Plasma beta-thromboglobulin (BTG) measured at 0 to 3 weeks was elevated (greater than 43 ng/ml) in seven of 24 (29%) patients. All patients with coronary artery aneurysms had elevated BTG values. The mean BTG in the group with aneurysms was 72.3 ng/ml when measured during the first 3 weeks after onset of fever, and 87.7 ng/ml at 4 to 7 weeks. The group without aneurysms had mean BTG values of 29.4 and 28.3 ng/ml at 0 to 3 and 4 to 7 weeks, respectively. The difference between the two groups was significant (P less than 0.002) for both the initial and later values. An elevated BTG during the first 3 weeks after onset of fever was highly associated with aneurysm formation in our patients (P less than 0.007). No aneurysms occurred in patients with a normal BTG value.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6235335     DOI: 10.1016/s0022-3476(84)80114-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  25 in total

1.  Reduced Platelet miR-223 Induction in Kawasaki Disease Leads to Severe Coronary Artery Pathology Through a miR-223/PDGFRβ Vascular Smooth Muscle Cell Axis.

Authors:  Yuan Zhang; Yanfei Wang; Li Zhang; Luoxing Xia; Minhui Zheng; Zhi Zeng; Yingying Liu; Timur Yarovinsky; Allison C Ostriker; Xuejiao Fan; Kai Weng; Meiling Su; Ping Huang; Kathleen A Martin; John Hwa; Wai Ho Tang
Journal:  Circ Res       Date:  2020-06-29       Impact factor: 17.367

2.  Noncoronary cardiac abnormalities are associated with coronary artery dilation and with laboratory inflammatory markers in acute Kawasaki disease.

Authors:  Beth F Printz; Lynn A Sleeper; Jane W Newburger; L LuAnn Minich; Timothy Bradley; Meryl S Cohen; Deborah Frank; Jennifer S Li; Renee Margossian; Girish Shirali; Masato Takahashi; Steven D Colan
Journal:  J Am Coll Cardiol       Date:  2011-01-04       Impact factor: 24.094

3.  Long-term anticoagulation in Kawasaki disease: Initial use of low molecular weight heparin is a viable option for patients with severe coronary artery abnormalities.

Authors:  Cedric Manlhiot; Leonardo R Brandão; Zeeshanefatema Somji; Amy L Chesney; Catherine MacDonald; Rebecca C Gurofsky; Tarun Sabharwal; Nita Chahal; Brian W McCrindle
Journal:  Pediatr Cardiol       Date:  2010-04-30       Impact factor: 1.655

4.  Thrombocytopenia: a complication of Kawasaki disease.

Authors:  T Hara; Y Mizuno; H Akeda; J Fukushige; K Ueda; T Aoki; H Sunagawa; S Honda; T Hijii; Y Yamaguchi
Journal:  Eur J Pediatr       Date:  1988-01       Impact factor: 3.183

Review 5.  Pharmacological therapy for patients with Kawasaki disease.

Authors:  R V Williams; L L Minich; L Y Tani
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 6.  Vasculitis in childhood.

Authors:  I Roberti; L Reisman; J Churg
Journal:  Pediatr Nephrol       Date:  1993-08       Impact factor: 3.714

Review 7.  Kawasaki disease.

Authors:  Dong Soo Kim
Journal:  Yonsei Med J       Date:  2006-12-31       Impact factor: 2.759

8.  Recognition of a Kawasaki disease shock syndrome.

Authors:  John T Kanegaye; Matthew S Wilder; Delaram Molkara; Jeffrey R Frazer; Joan Pancheri; Adriana H Tremoulet; Virginia E Watson; Brookie M Best; Jane C Burns
Journal:  Pediatrics       Date:  2009-05       Impact factor: 7.124

9.  Pseudohyperkalaemia in Kawasaki disease.

Authors:  T Shimizu; Y Yamashiro; K Yabuta
Journal:  Eur J Pediatr       Date:  1992-07       Impact factor: 3.183

10.  Salicylate treatment in Kawasaki disease: high dose or low dose?

Authors:  T Akagi; H Kato; O Inoue; N Sato
Journal:  Eur J Pediatr       Date:  1991-07       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.